This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
In this article we discuss the challenges for manufacturers of therapeutics and diagnostics as they pursue the potential of companion diagnostics. Click below to read the article.
Are GLP-1 weight-loss therapies growing primarily by expanding the treatment population or by capturing share from existing obesity therapies? Obesity afflicts...
Introduction Historically, drug development within the neurology space has been characterized by the search for individual therapies that can arrest complex...
As the center of life sciences innovation increasingly shifts to China, companies must be ready for a more complex international arbitration landscape. In this...
Daniel Shack is a panelist during the session titled “Survey Says…” In recent proceedings, consumer survey evidence has been tendered. What’s it for? What’s it...
